{
    "nctId": "NCT00992225",
    "briefTitle": "A Study of LY573636-sodium in Patients With Metastatic Breast Cancer",
    "officialTitle": "Phase 2 Evaluation of a Once Every 28 Days Dosing Regimen for LY573636-sodium in Patients With Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 43,
    "primaryOutcomeMeasure": "Percentage of Participants With an Objective Overall Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Received at least 2 or more prior chemotherapy regimens for metastatic breast cancer.\n* Have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, cancer-related hormonal therapy, or other investigational therapy for at least 4 weeks. Patients who have received whole-brain radiation must wait 90 days.\n\nExclusion Criteria:\n\n* Serious pre-existing medical condition.\n* Have active central nervous system or leptomeningeal metastasis.\n* Current hematologic malignancies, acute or chronic leukemia.\n* Receiving Warfarin (Coumadin).\n* Have a history of radiation therapy involving more than 25% of the bone marrow.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}